Patents Examined by Elizabeth C. Kemmerer
  • Patent number: 11513128
    Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: November 29, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Christoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist
  • Patent number: 11512124
    Abstract: Provided herein are polypeptides comprising a modified fibronectin type III (Fn3) domain, wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is mutated, and wherein the solubility is enhanced relative to the solubility of a Fn3 domain in which the amino acid corresponding to residue 58 of SEQ ID NO: 1 is not mutated. Also provided are libraries comprising a plurality of the polypeptides and a method for identifying a polypeptide that binds to a target.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: November 29, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Aaron P. Yamniuk, Stanley R. Krystek
  • Patent number: 11512112
    Abstract: The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (IL)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of NF-?B and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL)-RANK signaling pathway, and suppresses the expression of a RANKL or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (TRAP), cathepsin K, or TNF receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration. Moreover, the peptide of the present invention can contribute to osteoblast differentiation by promoting the expression of osteoblast differentiation markers such as osteocalcin (OCN), osteoprotegerin (OPG), bone sialoprotein (BSP), or osteopontin (OPN).
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: November 29, 2022
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun-Mi Kim, Eung-Ji Lee, Tae-Hoon Lee, A-reum Han
  • Patent number: 11512121
    Abstract: Methods of synthetically producing, formulating and using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 are provided. Methods of using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 as therapeutic agents to affect long term patient outcomes, such as preventing severe respiratory exacerbations of underlying conditions that require medical intervention, including hospitalization are provided. Methods of producing recombinant human secretoglobins, analytical methods, pharmaceutical compositions, and methods of use to prevent the long term sequelae of acute and chronic respiratory conditions are provided.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: November 29, 2022
    Assignee: APC Research Assets, LLC
    Inventors: Aprile L. Pilon, Melissa E. Winn, John K. Zehmer
  • Patent number: 11505586
    Abstract: This invention relates to extracellular protein-protein interactions and their possible therapeutic uses. More particularly, this invention describes the interaction between Draxin, particularly fragments binding to ?-Netrins comprising SEQ ID NO.:1, 2 or 3, and variants thereof, with ?-Netrins, and the use of this interaction to disrupt ?-Netrin/Netrin receptor interactions. The invention also relates to diagnostic and/or therapeutic uses of Draxin or fragments or variants thereof, as well as to an antibody against Draxin inhibiting binding of Draxin to ?-Netrins. Further, the invention relates to fragments of ?-Netrins, in particular Draxin-binding Netrin1-fragments comprising SEQ ID NO.: 51 and variants thereof, as well as to an antibody against ?-Netrins inhibiting binding of ?-Netrins to Netrin receptors.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: November 22, 2022
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Christian Söllner, Xuefan Gao, Christiane Nüsslein-Volhard
  • Patent number: 11497794
    Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: November 15, 2022
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, John Knopf
  • Patent number: 11485787
    Abstract: The present invention relates to compositions and methods for the modulation RGMb-Neogenin-BMP signaling.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: November 1, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., Boston Children's Hospital
    Inventors: Rosemarie Dekruyff, Gordon J. Freeman, Dale Umetsu, Sanhong Yu, Yanping Xiao
  • Patent number: 11471510
    Abstract: Provided herein are methods for the treatment in a subject of anemia, anemia requiring RBC transfusion, low or intermediate-1-risk myelodysplastic syndromes (MDS), and/or non-proliferative chronic myelomonocytic leukemia (CMML) in any mammals wherein the methods comprise administration of Activin-ActRII signaling inhibitors to a subject in need of the treatment.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: October 18, 2022
    Assignees: CELGENE CORPORATION, ACCELERON PHARMA INC.
    Inventors: Kenneth M. Attie, Christopher Rovaldi, Abderrahmane Laadem
  • Patent number: 11472872
    Abstract: The present invention relates to antibodies which bind to TNF? and comprise a modified Fc region. The antibodies of the invention have improved resistance against proteolytic degradation and good effector functions and/or pharmacokinetic properties.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: October 18, 2022
    Assignee: Tillotts Pharma AG
    Inventor: Esther Maria Furrer
  • Patent number: 11471511
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: October 18, 2022
    Assignee: Altor Bioscience, LLC
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
  • Patent number: 11467169
    Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: October 11, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Christoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist
  • Patent number: 11452761
    Abstract: A method for inhibiting renal hypofunction in a non-human animal includes administering cat-derived erythropoietin to the non-human animal. The non-human animal may have renal hypofunction. The non-human animal may have chronic kidney disease and the renal hypofunction may be caused by the chronic kidney disease. The cat-derived erythropoietin may be administered repeatedly at a time interval of 7 to 30 days.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: September 27, 2022
    Assignee: KANEKA CORPORATION
    Inventors: Hirokazu Sakamoto, Hiroetsu Suzuki, Kentaro Katayama, Yuki Tochigi
  • Patent number: 11453727
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: September 27, 2022
    Assignee: SANOFI
    Inventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
  • Patent number: 11447554
    Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: September 20, 2022
    Assignees: Saitama Medical University, Daiichi Sankyo Company, Limited
    Inventors: Takenobu Katagiri, Kenji Osawa, Sho Tsukamoto, Shinnosuke Tsuji, Yoshirou Kawaguchi, Kensuke Nakamura
  • Patent number: 11433139
    Abstract: A vaccine composition for immunizing and/or protecting a mammal against an IL-31 mediated disorder is provided, wherein the composition includes: the combination of a carrier polypeptide and at least one mimotope selected from a feline IL-31 mimotope, a canine IL-31 mimotope, a horse IL-31 mimotope, and a human IL-31 mimotope; and an adjuvant. Such vaccines can be in the form of pharmaceutical compositions useful for treating or protecting mammals such as cats, dogs, horses, or humans against IL-31-mediated disorders.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: September 6, 2022
    Assignee: Zoetis Services LLC
    Inventors: Gary Francis Bammert, Steven Alan Dunham
  • Patent number: 11433134
    Abstract: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: September 6, 2022
    Assignee: AMGEN INC.
    Inventors: Christopher James Sloey, Jason Ko, Tiansheng Li
  • Patent number: 11434269
    Abstract: The present invention relates methods of treatment using BMP6 antagonists.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: September 6, 2022
    Assignee: Novartis AG
    Inventors: Feng Cong, William Dietrich, Nathalie George, Dong Liu, Asher Schachter, Aditi Soni, Jing Zhou
  • Patent number: 11414484
    Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: August 16, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
  • Patent number: 11389453
    Abstract: The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: July 19, 2022
    Assignee: Cyrano Therapeutics, Inc.
    Inventor: Robert I. Henkin
  • Patent number: 11390675
    Abstract: Siglec-15 binding molecules are provides. The molecules are typically an antibody or antigen binding fragment thereof that immunospecifically binds to Siglec-15. Siglec-15 ligand-binding molecules are also provided. The molecules are typically Siglec-15 polypeptide or fusion protein. Methods of using the molecules to reduce Siglec-15 mediated immunosuppression in a subject in need thereof are also provided.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: July 19, 2022
    Assignee: NEXTCURE, INC.
    Inventors: Linda Liu, Benjamin Dallas Flies, Solomon Langermann